Drug-induced immune thrombocytopaenia: results from the Berlin Case–Control Surveillance Study
Purpose Drug-induced immune thrombocytopaenia is a rare, serious condition that can be triggered by numerous medications. To characterize the spectrum of drugs associated with immune thrombocytopaenia (ITP) in the Berlin Case–Control Surveillance Study (FAKOS). Methods Adult hospitalized patients with new onset idiopathic, secondary or drug-induced acute ITP and hospital control patients were ascertained by active surveillance in 50 Berlin hospitals (>180 clinical departments) between 2000 and 2009. Drug exposures were obtained in a personal interview. Chronic cases were excluded in a follow-up after 6 or more months. A standardized causality assessment was conducted for each ITP patient to assess possible drug aetiology. Drug risks were quantified in a case–control design with unconditional logistic regression analysis. Results Ninety out of 169 validated cases of acute ITP were assessed as being at least possibly drug-related (n = 85 different drugs overall, n = 30 drugs with certain or probable causality). Drugs involved in ≥2 cases with a probable or certain relationship were tirofiban (n = 10 cases), abciximab (n = 4), trimethoprim/sulphamethoxazole (n = 4), influenza vaccine (n = 3), and citalopram (n = 2). Pneumococcal and poliomyelitis vaccine were assessed as probably causing ITP in one case each. In the case–control analyses, significantly increased risks were observed for tirofiban, abciximab, trimethoprim/sulphamethoxazole, gentamicin, triamterene/hydrochlorothiazide, drospirenone/ethinylestradiol, and influenza vaccination. Conclusions Our study confirms known ITP risks for glycoprotein IIb/IIIa receptor antagonists and sulphonamides and generates signals for several other drugs and vaccines. New onset of ITP should not only direct attention to drugs as possible aetiological agents, but also to vaccines that are known to cause autoimmune phenomena..
| Medienart: |
Artikel |
|---|
| Erscheinungsjahr: |
2011 |
|---|---|
| Erschienen: |
2011 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:68 |
|---|---|
| Enthalten in: |
European journal of clinical pharmacology - 68(2011), 5 vom: 21. Dez., Seite 821-832 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Garbe, Edeltraut [VerfasserIn] |
|---|
| Links: |
Volltext [lizenzpflichtig] |
|---|
| Themen: |
Acute immune thrombocytopaenia |
|---|
| Anmerkungen: |
© Springer-Verlag 2011 |
|---|
| doi: |
10.1007/s00228-011-1184-3 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
OLC2064101357 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | OLC2064101357 | ||
| 003 | DE-627 | ||
| 005 | 20230512015602.0 | ||
| 007 | tu | ||
| 008 | 200819s2011 xx ||||| 00| ||eng c | ||
| 024 | 7 | |a 10.1007/s00228-011-1184-3 |2 doi | |
| 035 | |a (DE-627)OLC2064101357 | ||
| 035 | |a (DE-He213)s00228-011-1184-3-p | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 082 | 0 | 4 | |a 610 |q VZ |
| 082 | 0 | 4 | |a 610 |q VZ |
| 084 | |a 15,3 |2 ssgn | ||
| 084 | |a PHARM |q DE-84 |2 fid | ||
| 100 | 1 | |a Garbe, Edeltraut |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Drug-induced immune thrombocytopaenia: results from the Berlin Case–Control Surveillance Study |
| 264 | 1 | |c 2011 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ohne Hilfsmittel zu benutzen |b n |2 rdamedia | ||
| 338 | |a Band |b nc |2 rdacarrier | ||
| 500 | |a © Springer-Verlag 2011 | ||
| 520 | |a Purpose Drug-induced immune thrombocytopaenia is a rare, serious condition that can be triggered by numerous medications. To characterize the spectrum of drugs associated with immune thrombocytopaenia (ITP) in the Berlin Case–Control Surveillance Study (FAKOS). Methods Adult hospitalized patients with new onset idiopathic, secondary or drug-induced acute ITP and hospital control patients were ascertained by active surveillance in 50 Berlin hospitals (>180 clinical departments) between 2000 and 2009. Drug exposures were obtained in a personal interview. Chronic cases were excluded in a follow-up after 6 or more months. A standardized causality assessment was conducted for each ITP patient to assess possible drug aetiology. Drug risks were quantified in a case–control design with unconditional logistic regression analysis. Results Ninety out of 169 validated cases of acute ITP were assessed as being at least possibly drug-related (n = 85 different drugs overall, n = 30 drugs with certain or probable causality). Drugs involved in ≥2 cases with a probable or certain relationship were tirofiban (n = 10 cases), abciximab (n = 4), trimethoprim/sulphamethoxazole (n = 4), influenza vaccine (n = 3), and citalopram (n = 2). Pneumococcal and poliomyelitis vaccine were assessed as probably causing ITP in one case each. In the case–control analyses, significantly increased risks were observed for tirofiban, abciximab, trimethoprim/sulphamethoxazole, gentamicin, triamterene/hydrochlorothiazide, drospirenone/ethinylestradiol, and influenza vaccination. Conclusions Our study confirms known ITP risks for glycoprotein IIb/IIIa receptor antagonists and sulphonamides and generates signals for several other drugs and vaccines. New onset of ITP should not only direct attention to drugs as possible aetiological agents, but also to vaccines that are known to cause autoimmune phenomena. | ||
| 650 | 4 | |a Acute immune thrombocytopaenia | |
| 650 | 4 | |a Drug-induced | |
| 650 | 4 | |a Vaccines | |
| 650 | 4 | |a Case–control study | |
| 650 | 4 | |a Drug-dependent antibodies | |
| 700 | 1 | |a Andersohn, Frank |4 aut | |
| 700 | 1 | |a Bronder, Elisabeth |4 aut | |
| 700 | 1 | |a Salama, Abdulgabar |4 aut | |
| 700 | 1 | |a Klimpel, Andreas |4 aut | |
| 700 | 1 | |a Thomae, Michael |4 aut | |
| 700 | 1 | |a Schrezenmeier, Hubert |4 aut | |
| 700 | 1 | |a Hildebrandt, Martin |4 aut | |
| 700 | 1 | |a Späth-Schwalbe, Ernst |4 aut | |
| 700 | 1 | |a Grüneisen, Andreas |4 aut | |
| 700 | 1 | |a Meyer, Oliver |4 aut | |
| 700 | 1 | |a Kurtal, Hanife |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t European journal of clinical pharmacology |d Springer-Verlag, 1970 |g 68(2011), 5 vom: 21. Dez., Seite 821-832 |w (DE-627)129300438 |w (DE-600)121960-1 |w (DE-576)01449289X |x 0031-6970 |7 nnns |
| 773 | 1 | 8 | |g volume:68 |g year:2011 |g number:5 |g day:21 |g month:12 |g pages:821-832 |
| 856 | 4 | 1 | |u https://doi.org/10.1007/s00228-011-1184-3 |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_OLC | ||
| 912 | |a FID-PHARM | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a SSG-OLC-DE-84 | ||
| 912 | |a SSG-OPC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_105 | ||
| 912 | |a GBV_ILN_2006 | ||
| 912 | |a GBV_ILN_2012 | ||
| 912 | |a GBV_ILN_2018 | ||
| 912 | |a GBV_ILN_4012 | ||
| 912 | |a GBV_ILN_4028 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4219 | ||
| 912 | |a GBV_ILN_4277 | ||
| 951 | |a AR | ||
| 952 | |d 68 |j 2011 |e 5 |b 21 |c 12 |h 821-832 | ||